Circulating Biomarkers Predict Neurological Outcome After Cardiac Arrest

NCT ID: NCT02297776

Last Updated: 2014-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

160 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-08-31

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prediction of clinical outcome after cardiac arrest is clinically important.Early prognostication after successful cardiopulmonary resuscitation is difficult, and there is a need for novel methods to estimate the extent of brain injury and predict outcome. In this study, the investigators will evaluate the plasma levels of microRNAs (miRNAs) and circRNAs after cardiac arrest and assessed their ability to prognosticate neurological outcome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Diagnostic criteria for cardiac arrest Sudden loss of consciousness, carotid or femoral artery pulse disappeared, ECG showed ventricular asystole or ventricular fibrillation or ventricular tachycardia.
2. Diagnostic criteria for ROSC Recovery of complexion, autonomous aorta pulse can be detected, blood pressure\> 90/60 mmHg, the condition above maintained stable for more than half an hour, defined as ROSC, otherwise as failed.
3. Clinical treatment CPR was applied according to the AHA2010 guidelines. Patients were admitted to SICU or EICU after confirmation of ROSC, and physical cooling machines were set at 33 degrees Celsius to protect brain within 24h after ROSC. Standard treatments for life support were performed for all the included patients.
4. Methods 4.1 Clinical data Data such as patient's age, gender, contact information, previous disease information, the major reason causing cardiac arrest, initial rhythm, the total time of CPR, utilization of an automatic chest compression device, time from cardiac arrest to ROSC and time from cardiac arrest to ICU admission was collected from each patient who was included in the study. Follow-up data for APARCHE II (acute physiology and chronic health evaluation scoring system) score, survival of 24 hours after cardiac arrest, survival of 48 hours after cardiac arrest, survival of 28 days after admission, CPC score 2 weeks after cardiac arrest and CPC score 6 months after cardiac arrest were collected.

4.2 Cerebral Performance Category (CPC) CPC is a 5-category scale for measuring neurological status 2 weeks after cardiac arrest and CPC score 6 months after cardiac arrest. The 5 categories are: CPC 1, conscious and alert with good cerebral performance; CPC 2, conscious and alert with moderate cerebral performance; CPC 3, conscious with severe cerebral disability; CPC 4, comatose or in persistent vegetative state; and CPC 5, brain dead, circulation preserved.

4.3 Sample collection and processing Whole blood sample was collected into Ethylene diamine tetra-acetic acid (EDTA) -anticoagulant tube from each patient immediately at the beginning of CPR, 24h, 48h and 7 days after cardiac arrest. Samples were centrifugated and the supernatant was stored in EP tube with out RNA enzyme at -80 degree Celsius.

4.4 Detection of miRNA and circRNA Patients were divided into two groups according to the Cerebral Performance Category (CPC) after half a year, "CPC 1-2 Group" and "CPC 3-5 Group". Five samples for 48h time point in each group were randomly selected and detected miRNA and circRNA with chips.The real-time quantitative PCR were used to detect the quantity of the selected miRNAs and circRNAs for each time point. The plasma concentration of NSE for each time point was tested by laboratory department.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Arrest

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CPC score 1 to 2

The patients with CPC score 1 to 2 judged half a year after cardiac arrest

No interventions assigned to this group

CPC scores 3 to 5

The patients with CPC score 3 to 5 judged half a year after cardiac arrest

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Transferred to or hospitalized in the emergency department or other wards of Shanghai Tenth People's Hospital due to cardiac arrest;
2. Return of spontaneous circulation (ROSC)after cardiopulmonary resuscitation;
3. Age \> 14 years and \< 85 years;
4. Written informed consent was obtained from all patients'family members before entering the study.

Exclusion Criteria

1. No witnesses when cardiac arrest occurs;
2. Obvious neurological dysfunction prior to cardiac arrest;
3. Intracranial infection or cerebrovascular accidents as primary disease or secondary complication within six months in the follow-up period.
Minimum Eligible Age

14 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shanghai 10th People's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chen Yuanzhuo

M.D.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yuanzhuo Chen, MD

Role: STUDY_CHAIR

Shanghai 10th People's Hospital

Wenjie Li, MD

Role: PRINCIPAL_INVESTIGATOR

Shanghai 10th People's Hospital

Huiqi Wang, MD

Role: PRINCIPAL_INVESTIGATOR

Shanghai 10th People's Hospital

Chengjin Gao, MD

Role: STUDY_DIRECTOR

Shanghai 10th People's Hospital

Hu Peng, MD

Role: STUDY_DIRECTOR

Shanghai 10th People's Hospital

Yugang Zhuang, MD

Role: PRINCIPAL_INVESTIGATOR

Shanghai 10th People's Hospital

Xiangyu Zhang, MD

Role: STUDY_DIRECTOR

Shanghai 10th People's Hospital

Qixing Wang

Role: PRINCIPAL_INVESTIGATOR

Shanghai 10th People's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shanghai Tenth Hospital

Shanghai, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yuanzhuo Chen, MD

Role: CONTACT

+821666304586

Wenjie Li, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yuanzhuo Chen, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Zhuang YG, Chen YZ, Zhou SQ, Peng H, Chen YQ, Li DJ. High plasma levels of pro-inflammatory factors interleukin-17 and interleukin-23 are associated with poor outcome of cardiac-arrest patients: a single center experience. BMC Cardiovasc Disord. 2020 Apr 15;20(1):170. doi: 10.1186/s12872-020-01451-y.

Reference Type DERIVED
PMID: 32293300 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

040114001

Identifier Type: -

Identifier Source: org_study_id